AUS
NZ
UK
CA
USA
IND
Highlights:
HaemaLogiX, an Australian biotech focused on blood cancer treatments, is preparing for an ASX IPO in 2025.
The company has already raised significant funding, including a pre-IPO capital raise.
HaemaLogiX is advancing its CAR-T immunotherapy, with its first human trial set to begin in 2025.
HaemaLogiX, an Australian biotechnology company specializing in blood cancer treatments, is gearing up for an Initial Public Offering (IPO) on the Australian Securities Exchange (ASX) in 2025. The company, which counts former Macquarie Group (ASX:MQG) CEO Allan Moss and Platinum Asset Management among its shareholders, has enlisted Jefferies and Ord Minnett to support its IPO preparations. The company hopes to raise a substantial amount from the offering, which is planned for the second quarter of the new year.
As a private entity, HaemaLogiX has already raised $24.1 million and is currently undertaking a pre-IPO capital raise. The company aims to secure between $15 million and $20 million by mid-December. These funds are crucial for advancing its clinical trials and further developing its innovative therapies.
HaemaLogiX focuses on addressing blood cancers such as multiple myeloma, a type of bone marrow cancer that affects a significant number of Australians. The company is collaborating with the renowned Peter MacCallum Cancer Centre to conduct the first human trial of its CAR-T immunotherapy, KMA.CAR-T, specifically for kappa-type multiple myeloma. The first patient is expected to be treated in the second quarter of 2025, marking a key milestone in the company's clinical development.
In addition to its work in cancer treatment, HaemaLogiX is also exploring the potential of its therapies for autoimmune diseases, including amyloidosis. The funds raised through the upcoming capital raise will primarily support the fourth clinical trial of HaemaLogiX's KappaMab immunotherapy, which has shown promising results in prior trials.
HaemaLogiX's leadership includes Dr. Rosanne Dunn, Bryce Carmine, and board chair Dr. John Cullity. The company's managing director, Damian Clarke-Bruce, has experience leading other biotech firms, further bolstering confidence in HaemaLogiX's future prospects. With 75 patent filings and a strong commitment to innovative treatments, HaemaLogiX is positioning itself as a significant player in the Australian healthcare sector.
